Arcellx

Gilead offices
#Advanced Therapies #Arcellx #CAR-T #Cell therapy #Gilead Sciences #Mergers and acquisitions

Gilead Sciences to acquire CAR-T company Arcellx

Gilead Sciences has entered into a definitive agreement to acquire Arcellx for an equity value of $7.8 billion.   Arcellx is a biotechnology company focused on delivering a new class of immunotherapies for patients with cancer and other incurable diseases.  The companies have an existing collaboration… Read More

#Business & Investment #News #Trending News

Myeloma cells
#Arcellx #ASH 2025 #Myeloma

Anito-cel could be ‘significant’ treatment for myeloma 

Biotechnology company Arcellx has announced positive data from the Phase II study of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma (RRMM).  Results from the iMMagine-1 study demonstrate deep and durable responses with a predictable and manageable safety profile in a fourth-line or higher (4L+) RRMM population,… Read More

#Cancer Research #News

Multiple myeloma
#Arcellx #CAR-T #Cell therapy #Clinical trial #Haematology #Myeloma #Oncology #Phase I trial

CART-ddBCMA trial shows durable response in myeloma patients

Arcellx has revealed encouraging interim data from its Phase I study of CART-ddBCMA in patients with relapsed or refractory multiple myeloma. The company plans to present new data with a median follow-up of 26.5 months at the 65th American Society of Hematology (ASH) Annual Meeting and… Read More

#Cancer Research #News

Multiple myeloma
#Arcellx #Cancer research #Cell therapy #Collaboration #Kite #Myeloma #Partnership #T cell activation

Partnership will co-develop cell therapy for multiple myeloma

Kite and Arcellx have entered a global strategic collaboration to co-develop and co-commercialise CART-ddBCMA for the treatment of patients with relapsed or refractory multiple myeloma.  Currently in Phase II clinical development, CART-ddBCMA is an investigational cell therapy product comprising autologous T cells that have been genetically modified… Read More

#Cancer Research #News